Article

Cell

NRF2 Promotes Tumor Maintenance by Modulating **mRNA** Translation in Pancreatic Cancer

Graphical Abstract



Authors

lok In Christine Chio, Seyed Mehdi Jafarnejad, Mariano Ponz-Sarvise, ..., Darryl J. Pappin, Nahum Sonenberg, David A. Tuveson

Correspondence

dtuveson@cshl.edu

In Brief

Pancreatic tumors are sustained through NRF2 which protects regulators of translation from oxidation and potentiates EGFR signaling, supporting a synergistic therapeutic effect of prooxidants and small molecules targeting the EGFR effector AKT.

Highlights

- Nrf2 supports pancreatic tumor maintenance
- Nrf2 inhibits oxidation of specific translational regulatory factors
- Nrf2 promotes EGFR signaling to fuel cap-dependent mRNA translation
- Combined targeting of AKT and glutathione synthesis inhibits pancreatic cancer





NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer

Iok In Christine Chio,^{1,2} Seyed Mehdi Jafarnejad,³ Mariano Ponz-Sarvise,^{1,2,10} Youngkyu Park,^{1,2} Keith Rivera,¹ Wilhelm Palm,⁴ John Wilson,¹ Vineet Sangar,⁵ Yuan Hao,¹ Daniel Öhlund,^{1,2} Kevin Wright,^{1,2} Dea Filippini,^{1,2} Eun Jung Lee,^{1,2} Brandon Da Silva,^{1,2} Christina Schoepfer,^{1,2} John Erby Wilkinson,⁶ Jonathan M. Buscaglia,⁷ Gina M. DeNicola,⁸ Herve Tiriac,^{1,2} Molly Hammell,¹ Howard C. Crawford,⁶ Edward E. Schmidt,⁹ Craig B. Thompson,⁴ Darryl J. Pappin,¹ Nahum Sonenberg,³ and David A. Tuveson^{1,2,*}

¹Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA

²Lustgarten Foundation Pancreatic Cancer Research Laboratory, Cold Spring Harbor, NY 11724, USA

³Department of Biochemistry and Goodman Cancer Research Centre, McGill University, Montreal, QC H3A 1A3, Canada

⁴Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

⁵Institute of Systems Biology, 401 Terry Avenue N, Seattle, WA 98109, USA

⁶Departments of Molecular & Integrative Physiology and Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA

⁷Division of Gastroenterology, Department of Medicine, Stony Brook University School of Medicine, Stony Brook, NY 11794, USA

⁸Meyer Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA

⁹Department of Microbiology and Immunology, Montana State University, Bozeman, MT 59718, USA

¹⁰Present address: Department of Oncology, Clinica Universidad de Navarra, CIMA, IDISNA, Pamplona 31008, Spain

*Correspondence: dtuveson@cshl.edu

http://dx.doi.org/10.1016/j.cell.2016.06.056

SUMMARY

Pancreatic cancer is a deadly malignancy that lacks effective therapeutics. We previously reported that oncogenic Kras induced the redox master regulator Nfe2l2/Nrf2 to stimulate pancreatic and lung cancer initiation. Here, we show that NRF2 is necessary to maintain pancreatic cancer proliferation by regulating mRNA translation. Specifically, loss of NRF2 led to defects in autocrine epidermal growth factor receptor (EGFR) signaling and oxidation of specific translational regulatory proteins, resulting in impaired cap-dependent and cap-independent mRNA translation in pancreatic cancer cells. Combined targeting of the EGFR effector AKT and the glutathione antioxidant pathway mimicked Nrf2 ablation to potently inhibit pancreatic cancer ex vivo and in vivo, representing a promising synthetic lethal strategy for treating the disease.

INTRODUCTION

Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related death in the United States, with incidence nearly matching mortality. This is reflected by a short median survival of 6 months and a 5-year survival of <5% (Siegel et al., 2015). The poor prognosis of PDA relates to the advanced disease stage at the time of diagnosis and to its profound resistance to therapies (Jemal et al., 2009). PDA exhibits a wide range of genetic and epigenetic alterations, including a high frequency (90%–95%) of activating *KRAS* mutations and inactivation of the

tumor suppressors *TP53*, *P16/INK4A*, and *SMAD4* (Jones et al., 2008). We previously found that oncogenic *Kras* expression induced an important regulator of redox control, the transcription factor nuclear factor erythroid-derived 2-like 2, *Nfe2I2/Nrf2* (De-Nicola et al., 2011). In response to oxidative stress, Nrf2 controls the fate of cells through transcriptional upregulation of antioxidant-response-element-bearing genes (Hayes and Dinkova-Kostova, 2014). In the context of oncogenic Kras, Nrf2 promotes pancreatic intraepithelial neoplasia by stimulating proliferation and suppressing senescence. Thus, Nrf2 is a key player in PDA initiation through the maintenance of redox homeostasis.

Although oxidative stress may disrupt biological functions, redox reactions in a cell are often tightly regulated and play essential physiological roles (Trachootham et al., 2008). The chemical properties of cysteine thiol groups render this amino acid exquisitely sensitive to changes in the cellular levels of reactive oxygen species (ROS) or reactive nitrogen species (RNS). Certain cysteine thiols can act as redox switches, since oxidative modifications may impact properties such as catalytic activity or conformation of a protein (Barford, 2004). Although the general concepts of redox signaling have been established, the identity and function of many regulatory switches remain unclear, particularly in the context of cancer. Given the elevated levels of Nrf2 in PDA and the ability of Nrf2 to potently lower ROS, we hypothesized that such redox switches may function as Nrf2 downstream effectors to support PDA progression.

The cellular response to stress involves regulatory changes in many processes, including transcription, mRNA processing, and translation. Historically, increased cancer cell proliferation has been shown to require increased rates of protein synthesis and ribosome number (Johnson et al., 1975; Zetterberg et al., 1995). Mutations that deregulate mRNA translation are common events in human cancers (Bilanges and Stokoe, 2007), while

enforced expression of certain translation factors transforms rodent fibroblasts and promotes tumorigenesis (Wendel et al., 2004). Small molecules that target these pathways suppress mRNA translation and have anti-tumor effects (Choo and Blenis, 2009). Thus, deregulation of translation is an important step in oncogenic transformation and tumor maintenance. Here, we show that Nrf2 directly stimulates mRNA translation by maintaining the reduced state of specific cysteine residues in multiple proteins that participate in translational regulation. In parallel, redox regulation by Nrf2 also promotes epidermal growth factor receptor (EGFR) autocrine signaling through AKT in KRAS mutant cells to fuel cap-dependent translation initiation. These functions converge to promote global protein synthesis in PDA. Combined inhibition of AKT signaling and synthesis of glutathione, a vital intracellular antioxidant, synergistically hampered the survival of PDA cells in vitro and in vivo, which presents an opportunity for therapeutic intervention.

RESULTS

Nrf2 Is a Critical Biological Dependency in Pancreatic Cancer

The organoid culture system supports the proliferation of normal and malignant primary pancreatic ductal cells of both mouse and human origins (Boj et al., 2015). NRF2 protein was upregulated in human tumor (hT) organoids compared to normal counterparts (hN) (Figure S1A). While hN organoids tolerated NRF2 knockdown, this was detrimental in most hT organoids tested (three out of five) (Figure 1A). Upon NRF2 knockdown (Figure S1B), the two surviving hT organoids exhibited substantial elevation of ROS (Figure 1B) and decreased cell proliferation that was largely mitigated by the antioxidant N-acetylcysteine (NAC) (Figure S1C). Similar proliferative defects were also observed in the KRAS and TP53 mutant Suit2 PDA cell line (Moore et al., 2001) (Figure S1C). When transplanted into athymic nude mice, shNRF2 Suit2 cells gave rise to smaller tumors (Figure 1C. top). Likewise, doxycyline-induced knockdown of NRF2 (Figure S1D) in established, xenografted Suit2 tumors resulted in a significant decrease in tumor growth (Figure 1C, bottom). The level of DNA damage did not correlate with NRF2 expression in these tumors (Figure S1E) or in Suit2 cells and hT organoids in culture (Figure S1F). These data suggest that NRF2 is essential for PDA tumor maintenance through mechanisms other than prevention of ROS-induced DNA damage.

Given the difficulty of targeting transcription factors therapeutically, we sought to comprehensively characterize the mechanisms used by NRF2 to support PDA so that tractable approaches to counter the effects of NRF2 may be developed. To this end, we used organoids established from genetically engineered mouse models, which mimic the pathophysiological features of the human disease in a uniform genetic background (Hingorani et al., 2005). Murine pancreatic organoid cultures were grown from the ductal isolates of normal (N), $Kras^{G12D/+}$ (K), and $Kras^{G12D/+};p53^{R172H/+}$ (KP) tissues of either Nrf2-wild-type or Nrf2-deficient (n) backgrounds. The resulting organoids appeared to be morphologically similar, as hollow structures with a singlecell layer (Figure S1G). While Nrf2-deficient organoids can be propagated in culture, orthotopic engraftment of K organoids in athymic nude mice was largely impaired in the absence of *Nrf2* (Figures 1D and 1E). This defect was cell autonomous, since syngeneic engraftment of K organoids was similar between a C57BL/6J host and one that was deficient in *Nrf2* (Figures 1D and 1E).

Pancreatic organoids are typically maintained in complete media, which contain various growth factors, including epidermal growth factor (EGF) and NAC. Oncogenic *Kras* upregulated *Nrf2* and its downstream target gene *Nqo1* in K and KP organoids (Figures S1H and S1I). The induction of *Nrf2* and *Nqo1* in KP organoids was more prominent upon exclusion of both EGF and NAC from the media (reduced) (Figures S1J and S1K). While removal of EGF and NAC limited the passaging capacity of N organoids, they were dispensable for K and KP organoids (Figure S1L). Thus, all organoids described hereinafter were cultured and passaged in complete media, while experiments were all conducted in reduced media.

Oncogenic *Kras* activation in K and KP organoids resulted in a significant increase in intracellular glutathione (GSH) (Figure S1M) and decreased levels of ROS (Figure S1N), features reverted upon Nrf2 ablation (Figures 1F, 1G, and S1M). Notably, no increases were observed in the levels of RNS (Figure S1O) or in mitochondrial superoxides (Figure S1P), upon either chronic ablation or acute knockdown of *NRF2* in murine tumor organoids (T organoids) and hT organoids, respectively. This indicates that NRF2 specifically modulates cytoplasmic ROS in pancreatic ductal cells. Deficiency of *Nrf2* impeded proliferation of N, K, and KP organoids in culture and was largely corrected by NAC (Figure 1H). KPn organoids did not exhibit elevated DNA damage response (Figure S1Q). Therefore, Nrf2 regulates redox homeostasis and cell proliferation in *Kras* mutant pancreatic epithelial cells, likely through a DNA-damage-independent mechanism.

Global Cysteine Proteomics Reveal Redox-Dependent Regulation of the Translational Machinery

Cysteine residues are the most abundant cellular thiol. Alterations in cellular redox levels may cause reversible modifications on specific cysteine residues and alter the activity of their corresponding proteins (Paulsen and Carroll, 2010). Thus, reactivecysteine-containing proteins are potential candidates to carry out the redox-sensitive effector functions of Nrf2. To decipher changes in the cysteine proteome, we devised a highly sensitive proteomic method using a selectively cleavable cysteine-reactive (ICAT) reagent to enrich for and identify reduced cysteinecontaining peptides (Sethuraman et al., 2004). This was combined with a parallel analysis of the total proteome by using amine-reactive isobaric tags for relative and absolute quantification (iTRAQ; Ross et al., 2004) (Figure 2A). By normalizing cysteine peptide changes to that of the total proteome, oxidative alterations in the cysteine proteome were quantified independent of protein expression differences, an approach not applied previously in cysteine proteomics. To establish this method, murine T organoids were treated with an inhibitor of GSH synthesis, buthionine sulfoximine (BSO). In this experiment, 88% of the ICAT-enriched unique peptides contained cysteines, indicating the specificity of the technique. From a total of 4,089 proteins identified and quantified, 4,805 unique cysteine-containing peptides were detected. Upon BSO treatment, 1,192 unique cysteine-containing peptides were oxidized. Notably, cysteine



Figure 1. Nrf2 Controls Redox Homeostasis, Initiation, and Maintenance of Pancreatic Tumors

(A) Human normal (N) and tumor (T, primary tumor; FNA, fine needle biopsy; M, metastasis) organoid lines following knockdown with control (shScramble; shScr) or shNRF2 hairpins. Scale bars, 1 mm. Red box indicates human T organoid lines that did not tolerate NRF2 loss.

(B) ROS levels in hT organoids measured with CM (chloromethyl)-H2DCFDA.

(C) Tumor volume of subcutaneously xenografted Suit2 cells bearing control or shNRF2 hairpins. (Top) Constitutive knockdown (n = 5) on day 28. Left flank: control tumor; right flank: shNRF2 tumor. (Bottom) Inducible knockdown 21 days post-transplantation followed by doxycycline treatment for 4 or 8 days (n = 17 control, and n = 6 mice per shNRF2 hairpin, Student's t test).

(D) H&E and immunohistochemistry (IHC) of orthotopic transplants of GFP-expressing K and Kn organoids into athymic nude mice 2 weeks after transplantation (left). H&E and IHC of orthotopic, syngeneic transplants of K organoids into B6 wild-type (WT) or $Nrf2^{-/-}$ mice 2 weeks after transplantation (right). Scale bars, 500 µm for 5× and 100 µm for 20×.

(E) Engraftment rates of orthotopic transplants.

(F) Ratio of reduced (GSH) to oxidized (GSSG) glutathione in murine organoids (n = 3, Student's t test).

(G) ROS levels in murine organoids measured with CM-H2DCFDA, representative of three biological replicates.

(H) Proliferation of N, K, and KP organoids grown in reduced media with or without 1.25 mM NAC.

Data are means \pm SEM (n = 5). *p < 0.05; NS, p > 0.05, Student's t test.

See also Figure S1.

residues oxidized by BSO included a previously reported redoxsensitive protein, Pkm2 (Anastasiou et al., 2011). The full list of oxidized peptides is shown in Table S1.

To identify Nrf2-dependent, redox-sensitive effector pathways, the cysteine proteomes of three pairs of N, Nn, K, and Kn and four pairs of KP and KPn organoids were normalized and merged. A total of 2,591 unique cysteine-containing peptides corresponding to 1,446 proteins were identified in all of the four 8-plex iTRAQ runs (MassIVE: MSV000079394). Of these, 56 cysteine-containing peptides were significantly oxidized when *Nrf2* was deleted in N organoids, 49 in K organoids, and 255 in KP organoids (Fig-

ure 2B; Table S2). As in BSO-treated tumor organoids, Pkm2^{C358} was also substantially oxidized in KPn organoids. Global levels of reduced cysteine peptides were similar across the different genotypes (Figure S2A), indicating the absence of widespread changes in protein oxidation upon *Nrf2* ablation. To determine whether the subset of proteins specifically oxidized in KPn cells represented any particular biochemical processes, the data were analyzed using DAVID (Huang et al., 2009) for pathway enrichment. Interestingly, proteins containing oxidized cysteines in KPn organoids were strongly enriched for participation in protein folding and in mRNA translation (Figure 2C). Nrf2-deficient

Α_		В		
	Cell lysis in anoxia	Total Unique Cysteine Peptides	2591	
Г	Cysteine labelling (ICAT)	Sig. oxidized in Nn vs N	56	
	<u>, , , , , , , , , , , , , , , , , , , </u>	Sig. oxidized in KPn vs KP	255	
	Reduce and MMTS reaction	C		
	Trypsinize			
	Typsinize	Category Term	Count % P 10 8 47457627	Value Fold Enrich Bonferroni Benjamini FDR 6 26E-07 9 99926411 6 58E-04 6 58E-04 9 96E-04
Г	Isobaric labelling (iTRAQ)	GOTERM_BP_FAT GO:0006412~translation	13 11.0169492	6.97E-06 5.17516773 0.00729579 0.00365457 0.01107715
	¥	GOTERM_BP_FAT GO:0030036~actin cytoskeletor	organization 9 7.62711864	4.39E-05 6.92676296 0.04504323 0.01524566 0.06970094
F	Pool samples. C18 clean up	GOTERM_BP_FAT GO:0030029*actin filament-bas GOTERM BP_FAT GO:0007010*cytoskeleton orga	nization 97.62/11864	6.92E-05 6.49384027 0.07018573 0.01802812 0.11002887 2.28E-04 4.28496072 0.21348708 0.04689407 0.36264166
	+	GOTERM_BP_FAT GO:0044271~nitrogen compound	nd biosynthetic process 9 7.62711864 0	.00248848 3.78448969 0.927099 0.35366811 3.8841378
Г	Streptavidin column	GOTERM_BP_FAT GO:0007015~actin filament org	anization 4 3.38983051 0	00948042 9.07076101 0.99995512 0.76074093 14.0544788
		GOTERM_BP_FAT GO:0051186~cofactor metaboli	c process 6 5.08474576 0	.01394389 4.18650508 0.99999961 0.80598033 20.0098131
C		GOTERM_BP_FAT GO:0043254~regulation of prot	ein complex assembly 4 3.38983051	0.0142056 7.81480949 0.99999971 0.77769717 20.3467072
Aci	d cleavage LC/MS = Total			
	+			
LC	/MS = Cys			
n				
U	Nn vs N	Kn vs K	KPn vs KP	KPn vs KP
	Eef2 (elongation)	Eef2 (Elongation)	Eif3j1 (Initation)	hnRNPk
	Rpl22 (60S)	Rps2 (40S)	Eif3d (Initiation)	FAM120a
	Rps4x (40S)	Rps3a2 (40S)	Eef1b2 (Elongation)	LARP
	Eif4g3 (Initiation)	Rps3a3 (40S)	Eef2 (Elongation)	FKBP5
	Vars (tRNA synthetase)	Vars (tRNA synthetase)	Gspt2 (Termination)	Gnb2l1
			Rps2 (40S)	Zc3hav1
			Rpl18 (60S)	APOBEC3
			Rps4x (40S)	OGDHL
			Rps20 (40S)	
			RpI7 (60S)	
			Vars (tRNA synthetase)	
			varo (anti roginatotaco)	

Figure 2. Nrf2 Deficiency Induces Cysteine Oxidation of Components of the Translation Machinery

(A) Schematic of cysteine proteomics approach. LC/MS, liquid chromatography/mass spectrometry.

(B) Significant (Sig.) cysteine peptide changes identified in N, K, and KP organoids compared to Nrf2 null counterparts. p < 0.05, Welch's t test.

(C) DAVID gene ontology (GO) analysis for pathway enrichment (Enrich) of significantly oxidized peptides in KPn organoids compared to KP organoids. FDR, false discovery rate.

(D) Proteins in the core translation machinery (blue) and regulators of mRNA translation (green) that were significantly oxidized (Welch's t test, p < 0.05) in *Nrf2*-deficient N, K, and KP organoids.

See also Figure S2 and Tables S1, S2, S3, and S4.

T organoids also exhibited a similar enrichment (Tables S3 and S4). Besides the classic translation pathway proteins curated in the DAVID database (ribosomal proteins and translation initiation and elongation factors), we identified additional proteins implicated in translational regulation to be oxidized in KPn organoids (Figures 2D and S2B), further coupling Nrf2 activation with translational control. Translation-related peptides exhibited an average of 20%-50% increase in oxidation in KPn organoids (Figure S2C), in line with studies conducted in yeast reporting that the majority of cysteine residues are only partially ($\sim 25\%$) oxidized (Brandes et al., 2011). Treatment of murine T organoids with BSO similarly led to significant oxidation of proteins in the translation machinery (Figures S2D and S2E). These genetic and pharmacological observations collectively support the redox-dependent regulation of the translation machinery through cysteine modifications, prompting us to further evaluate the functional role of Nrf2 in mRNA translation for pancreatic cancer cells.

mRNA Translation Is Impeded in Nrf2-Deficient Cells

mRNA translation is a vital cellular process that regulates growth and metabolism (Sonenberg and Hinnebusch, 2009). In cancer

ally active polysomes and decreased levels of mRNA associated with translationally inactive monosomes (Figure 3A, left), consistent with the notion that translational upregulation plays an oncogenic role in cancer. While deletion of Nrf2 from N and K organoids did not noticeably alter the distribution of monosomes and polysomes (Figure S3A), deletion of Nrf2 from KP organoids led to a measurable decrease in polysomes, with a corresponding increase in monosomes (Figure 3A, right), suggesting a decrease in translation efficiency in cancer cells when Nrf2 is absent. Impaired translation in KPn organoids was not due to eIF2 (eukaryotic initiation factor 2)-mediated activation of the unfolded protein response upon elevated ROS (Figure S3B) (Ling and Söll, 2010). When pulsed with [³⁵S]-methionine ([³⁵S]-Met) to measure the rate of nascent protein synthesis, a significant decrease in [35S]-Met incorporation was observed in Kn and KPn organoids (Figures 3B and S3C). This translation defect was redox dependent (Figure 3B) and was observed in

cells, hyper-activated signaling pathways influence translation,

supporting uncontrolled growth and survival (Mavrakis and

Wendel, 2008). When compared to N organoids, KP organoids

exhibited elevated levels of mRNA associated with translation-







organoids and Suit2 harboring short hairpin NRF2 (shNRF2) (Figures 3B, S3D, and S3E). These effects were mitigated by NAC and other antioxidants such as trolox and GSH ethyl ester (Figures 3B and S3D-S3F). Of note, treatment of organoids with propargy|g|ycine, an irreversible inactivator of γ -cystathonase, did not alter the difference in [35S]-Met incorporation into proteins in KP and KPn organoids (Figure S3G). This indicates that Nrf2-dependent decrease in [³⁵S]-Met incorporation into proteins was not due to alterations in Met to cysteine exchange through the transsulfuration cycle in response to elevated oxidative stress (Belalcázar et al., 2014). Introduction of a heterotypic NRF2 mRNA in hT organoids expressing short hairpin RNA (shRNA) against endogenous NRF2-restored [³⁵S]-Met incorporation (Figure S3H). Thus, Nrf2 regulates the activity of the translational machinery through the maintenance of redox homeostasis.

To further analyze the steps in mRNA translation that are impacted by Nrf2 in pancreatic cancer cells, a bicistronic reporter construct encoding Renilla luciferase under the simian virus 40 (SV40) promoter and firefly luciferase under the control of the IRES (internal ribosome entry site) sequences from the hepatitis C virus (HCV) was used. Interestingly, both cap-dependent translation of Renilla luciferase and cap-independent HCV-IRESmediated translation of firefly luciferase were decreased in Suit2 cells bearing shNRF2 (Figure 3C), with no significant changes in the expression of the luciferase gene (Figure S3I). While HCV-IRES-mediated translation requires certain canonical initiation factors (Otto and Puglisi, 2004), the cricket paralysis virus IRES (CPV-IRES) (Wilson et al., 2000) enables translation of mRNAs independently of any translation initiation factors. We found that CPV-IRES-mediated translation was also impaired when NRF2 expression was suppressed (Figure 3C). These translational defects were partially phenocopied by BSO treatment (Figure 3C) and were recapitulated in KPn organoids (Figure 3C). These results suggest that NRF2 exercises redox-dependent control over multiple aspects of the translation machinery.

Since cysteine residues previously implicated as functional redox switches are reversibly oxidized, we evaluated the possibility that components of the translational machinery may also be redox switches that govern translation activity. Supplementation of KPn organoids with NAC reversed the oxidative cysteine changes in a number of translational regulatory proteins (Figure 3D). shRNA-mediated knockdown of selected initiation and elongation factors (Figure S3J) confirmed that they were independently essential for protein synthesis in PDA (Figure 3E).

Ectopic expression of these factors did not enhance protein synthesis in KP organoids (Figure S3K). However, ectopic expression of the cysteine to aspartic acid oxidation mimic (Permyakov et al., 2012) of the elongation factor eEF2 led to a significant decrease in the rate of nascent protein synthesis when compared to its wild-type counterpart (Figures 3F and S3L). A similar trend was also observed for the translation initiation factor eIF3J but not for the ValyI-tRNA synthetase Vars (Figures 3F and S3L). These results suggest that eEF2^{Cys693} (and, possibly, additional components of the translation machinery) may function as a redox switch to modulate the activity of the elongation apparatus.

Growth Factor Signaling Pathways Upstream of Cap-Dependent Translation Are Impaired in Nrf2-Deficient Cells

Of the four phases of protein synthesis (initiation, elongation, termination, and recycling), initiation is considered to be the rate-limiting step in mRNA translation and is often exploited by cancer cells to support tumorigenesis (Pelletier et al., 2015). Based on our observation that cap-dependent mRNA translation was compromised in NRF2-deficient cells (Figure 3C), and that the initiation factor eIF3J may also be a candidate redox switch (Figure 3F), we extended our investigation on translation initiation biochemically. eIF4E is the limiting initiation factor for mRNA translation, as it recognizes the m'GTP cap on mRNA and recruits elF4G (Gingras et al., 1999). In the absence of mitogenic signaling, eIF4E is bound by the inhibitory 4E binding proteins (4EBPs), which sequester elF4E from interaction with elF4G. This process is critical for regulating mRNA translation in PDA organoids, as expression of a dominant active 4EBP1-4A mutant led to substantial decrease in nascent protein synthesis (Figure S4A) and cell proliferation (Figure S4B), phenocopying Nrf2 deficiency. The levels of eIF4E, eIF4G, and 4EBP1 were independent of Nrf2 status (Figure 4A; Figure S4C), and the oxidative states of these proteins as determined through iodoacetamide enrichment for reduced cysteine peptides were also similar in KP and KPn cells (Figure S4C). Despite these, the amount of inhibitory 4EBP1 co-precipitating with eIF4E in m⁷GTP pull-downs was found to be elevated in Nn, Kn, and KPn organoids, with a concomitant decrease in eIF4G co-precipitation (Figures 4A and S4D). This reflects a defective eIF4F complex formation that would impart decreased cap-dependent translation initiation in Nrf2-deficient KP cells.

Figure 3. Nrf2 Deficiency Impairs Protein Synthesis

⁽A) Polysome profiles of N, KP, and KPn organoids treated with 300 μ g/ml cycloheximide for 10 min. Absorbance light at 254 nm. Representative profiles from two biological replicates.

⁽B) $[^{35}S]$ -Met incorporation into protein from murine and human organoids grown in reduced media or in media containing 1.25 mM NAC. Data are means \pm SEM (n = 3, Student's t test). NS, not significant.

⁽C) Activities of *Renilla* and firefly luciferase in Suit2 cells bearing shScr or sh*NRF2* (left three graphs) or KP or KPn organoids (rightmost) transfected with the biscistronic reporter plasmid 24 hr prior. Data indicate percentage luciferase activity driven by SV40-CAP, HCV-IRES, or CPV-IRES. Data are means ± SD (n = 3, Student's t test). Unt, untreated.

⁽D) Cysteine peptide counts of translational regulatory proteins in KP, KPn, and KPn organoids supplemented with 1.25 mM NAC (average of two biological replicates).

⁽E and F) [³⁵S]-Met incorporation into protein from murine T organoids bearing shRNA (E) or V5-tagged wild-type (WT) or cysteine-mutated (CD) cDNAs of indicated proteins (F). Data are means ± SEM (n = 6, Student's t test). See also Figure S3.



Figure 4. Nrf2 Deficiency Impairs Mitogenic Signaling Pathways Governing eIF4F Complex Formation

(A) Lysates from KP and KPn organoids were subjected to 7-methyl-GTP pull-downs and analyzed for indicated proteins. WCL, whole-cell lysates. (B and C) Immunoblot analysis for growth factor signaling pathway activation (B) and mRNA cap-binding proteins (C) in N, K, and KP organoids, as well as murine tumor (T) and hT (hM1, hT3) organoids with shScr or sh*NRF2*. p, phospho.

(D and E) Immunoblot analysis of total (D) and EGFR tyrosine (Y) phosphorylation (E) in KP and KPn organoids. Red arrow indicates 150-kDa molecular-weight protein. 4G10 IP, total phospho-Y antibody immunoprecipitation.

(F) Protein array analysis for growth factors secreted into culture medium (Supernatant) and expressed in whole-cell lysates (WCL) in KP and KPn organoids. Red box indicates murine EGF.

(G) EGF ELISA of supernatant from N, Nn, KP, and KPn organoids after 3 or 6 days in culture. Data are means \pm SD (n = 3, Student's t test).

(H) Constitutive EGF shedding determined by alkaline phosphatase activity in the supernatant from KP organoids. Data are means \pm SD (n = 3, Student's t test). (I and J) Activity of Adam10 from plasma membrane fractions of KP, KPn, and K;Adam10 knockout (KAdam^{KO}) organoids (I) or KP organoids expressing control vector versus Adam10 cysteine mutant (CD) (J), measured by cleavage and increase in 5-FAM (5-carboxyfluorescein) fluorescence of a FRET (fluorescence)

(legend continued on next page)

PI3K (phosphatidylinositol 3-kinase)/AKT/mTOR signaling has been shown to promote phosphorylation of 4EBPs at multiple sites, resulting in the liberation of eIF4E from 4EBP1 and the stimulation of cap-dependent translation initiation (Ruggero and Sonenberg, 2005). Consistent with elevated 4EBP1 at the mRNA cap, phosphorylation of Akt and 4EBP1 were both decreased in Kn and KPn organoids, as well as in murine T organoids and hT organoids expressing shNRF2 (Figure 4B). pErk was moderately decreased in Kn and KPn cells and more clearly decreased in T organoids expressing shNRF2 (Figure 4B). The level of pS6 was not consistently downregulated in Kn and KPn cells, suggesting that these signaling alterations operate independently of S6 kinase (Figure 4B). Consistently, phosphorylation of eIF4G and eIF4E-substrates of Akt/mTOR (Raught et al., 2000) and Erk/Mnk signaling (Ueda et al., 2004)-respectively, were also decreased in Kn and KPn organoids, as well as in T organoids expressing shNRF2 (Figures 4C, S4E, and S4F). These signaling defects were not due to differential activation of oncogenic Kras (Figure S4G) or that of the IGF1 (insulin-like growth factor 1) receptor (Figure S4H) (Molina-Arcas et al., 2013). Neither the activity nor the expression level of PTEN (Maehama and Dixon, 1998) was upregulated in Nn and KPn organoids (Figure S4I). The signaling changes upon Nrf2 deficiency were most striking in the context of K and KP cells, reflecting critical Kras dependency.

A hallmark of Kras mutant cells is the role of autocrine and paracrine loops in amplifying oncogenic Kras signaling through AKT and ERK (extracellular signal-regulated kinase) (Ardito et al., 2012). Decreased activation of AKT and MAPK in Nrf2deficient cells was not due to oxidation of these kinases (Figure S4J). Immunoblot analysis of global tyrosine phosphorylation revealed decreased phosphorylation of a protein above 150 kDa (Figure 4D), which we then confirmed to be the EGFR (Figure 4E). By secretome arrays (Figure 4F) and ELISA (Figure 4G), we found that the release of EGF into culture media by KPn organoids was reduced when compared to that by KP organoids, while total intracellular levels of EGF protein (Figure 4F) and mRNA (Figure S4K) were not decreased. Indeed, induced (Figure S4L) and constitutive (Figure 4H) shedding of EGF-as determined by the expression of an EGF-alkaline phosphatase (AP) construct, followed by measurement of AP activity in the supernatantrevealed decreased EGF shedding in KPn organoids and in Nrf2-deficient tumor cells (Figure S4M). Consistent with reports showing that EGFR signaling is coupled to activation of capdependent translation in EGFR wild-type cells (Patel et al., 2013), EGF supplementation was able to restore defective Akt and Erk activation in KPn organoids (Figure S4N). Addition of NAC alone also partially corrected these signaling defects (Figure S4N) and restored EGF release (Figure S4O). As with NAC supplementation, EGF was sufficient to mitigate the translational defects observed in Kn and KPn organoids (Figure S4P) and improved proliferation in KPn organoids (Figure S4Q). Doxcycline-induced knockdown of NRF2 in hT organoids led to decreased phospho-(p)EGFR and pERRB2 (Figure S4R). Similarly, the activity levels of EGFR in tumor lysates of Suit2 xenografts correlated with doxycycline-induced *NRF2* knockdown (Figure S4S). In one sh*NRF2* tumor sample where NRF2 was reactivated, pEGFR was sustained at a high level (Figure S4S), further demonstrating a role of NRF2 in EGFR activation.

Metalloproteases of the ADAM (a disintegrin and metalloprotease) family are thought to be responsible for the shedding of certain EGFR ligands, with Adam10 emerging as the main sheddase of EGF (Sahin et al., 2004). Although Adam10 was not detected in our initial cysteine proteomics experiment, mass spectrometric analysis of immunoprecipitated Adam10 revealed a substantial and specific decrease in the levels of a cysteinecontaining peptide when Nrf2 was deleted (Figure S4T). Consistent with decreased EGF shedding, Adam10 was functionally impaired in KPn organoids (Figure 4I). Ectopic expression of a cysteine oxidation mimic of Adam10 (Figure S4U) inhibited the activity of endogenous Adam10 (Figure 4J) and led to a significant decrease in nascent protein synthesis in KP organoids (Figure 4K). These data suggest that redox-dependent regulation of Adam10 activity contributes to the maintenance of EGF autocrine signaling and cap-dependent translation in PDA.

Nrf2 Supports Cap-Dependent Translation of Prosurvival Transcripts

Enhanced eIF4F complex formation in cancer cells promotes cap-dependent mRNA translation and, thereby, elevates global protein synthesis rates. However, mRNAs vary widely in their inherent "translatability," largely as a function of differences in the length and structure of their 5' UTRs. Cellular mRNAs most sensitive to alterations in eIF4F complex formation have highly structured 5' UTRs. These mRNAs often encode proteins that promote growth and transformation (Pelletier et al., 2015). In contrast, the majority of cellular mRNAs have relatively short, unstructured 5' UTRs that enable efficient translation, even when elF4F complex levels are limiting. We found that the levels of a number of pro-survival proteins were increased in KP compared to N organoids, with no changes in housekeeping proteins (Figure 5A; Figure S5A). Of the pro-survival proteins, Hif1a, Bcl2, and more moderately, cyclin D1, cyclin D3, and c-Myc were decreased in KPn organoids (Figure 5A). Similar observations were made in murine T organoids bearing shNrf2 (Figure 5B). This is consistent with earlier reports showing a correlation between the expression of Nrf2 and some of these proteins (Fan et al., 2014; Ke et al., 2013; Malec et al., 2010; Niture and Jaiswal, 2012; Wang et al., 2016). qPCR of polysome fractions revealed an increase in the association of the mRNAs of these proteins with the translationally inactive monosome fractions (Figure 5C), while no differences were seen for Actin, Mcl-1, and, interestingly, Bcl2 mRNAs (Figure S5B). No decrease was observed in the total transcript level of these mRNAs (Figure S5C) or the half-life of the corresponding proteins (Figure S5D).

- (K) [³⁵S]-Met incorporation into protein from KP organoids expressing control vector or Adam10 cysteine mutant (CD). Data are means ± SD (n = 6, Student's t test).
- See also Figure S4.

resonance energy transfer) substrate specific to Adam 10. Activity was monitored over 2 hr at excitation, excitation/emission = 490 nm/520 nm. Data are means \pm SD (n = 2).



Figure 5. Nrf2 Supports Translation of Pro-survival Transcripts

(A and B) Immunoblot analysis of oncoproteins in N and KP organoids (A) and murine T organoids (B) expressing shScr or shNrf2.

(C) qPCR analysis of indicated mRNAs from polysome fractions of KP and KPn organoids. CT of each fraction minus CT of 80S fraction (Δ CT). Data are means normalized against the sum \pm SD (n = 2 biological replicates). Fractions 1–6 are monosomes; fractions 7–12 are polysomes.

(D) qPCR analysis of mRNA expression of Hif1 α target genes in murine T organoids. Data are means \pm SD (n = 3, Student's t test). Vegf, vascular endothelial growth factor.

(E) Proliferation of organoids grown in 21% or 3% oxygen. Data are means ± SEM (n = 5).

(F) Cell viability upon treatment with 20 mM 2-deoxyglucose (2-DG) for 72 hr in 21% oxygen or 5% oxygen. Data are means ± SEM (n = 5, Student's t test). See also Figure S5.

Compromised Hif1 α protein levels in KPn organoids corresponded with a decrease in the expression level of Hif1 α target genes (Figure 5D), their inability to grow in hypoxia (Figure 5E), and heightened sensitivity to inhibition of glycolysis (Figure 5F) (Semenza, 2013). These data indicate that Nrf2-mediated protein synthesis in *Kras* mutant cells has a potent impact on the translation of certain proto-oncogenic mRNAs, thus supporting a role for Nrf2 in fully transformed PDA cells.

Combined Inhibition of AKT and GSH Synthesis Blunts Pancreatic Cancer Growth and Survival

The PI3K/AKT/mTOR pathway is believed to be a major pathway regulating global and mRNA-specific translation initiation (Ruggero and Sonenberg, 2005). We found that the basal phosphorylation status of 4EBP1 correlated strongly with the sensitivity of hT organoids to sh*NRF2* (Figure 6A). Inhibition of AKT using the pan-AKT inhibitor MK2206 markedly decreased the rate of protein synthesis (Figure 6B) and increased 4EBP1-eIF4E interactions at the mRNA cap (Figure 6C) in KP organoids, the effects of which were potentiated in KPn organoids (Figures 6B and 6C). At a dose that suppressed KP intracellular GSH to a level found in KPn cells (Figure S6A), BSO bolstered the effect of MK2206 to further decrease the rate of protein synthesis (Figure 6D). Consistently, inhibition of 4EBP1 phosphorylation in both KP and hT organoids was most efficient in the presence of both inhibitors (Figure 6E).

Reactivation of EGFR and MAPK (mitogen-activated protein kinase) signaling upon inhibition of AKT is an important adaptive survival response, leading to drug resistance in *Kras* mutant cancer cells, and requires an intact autocrine EGFR signaling cascade to enact (Mendoza et al., 2011). Consistent with defective EGFR signaling in Kn and KPn organoids, these adaptive responses were attenuated (Figure S6B). While BSO treatment alone had minimal effects on the activity of these signaling



Figure 6. Inhibition of GSH Synthesis Sensitizes Pancreatic Cancer Cells to Pan-AKT Inhibition

(A) Immunoblot analysis of 4EBP1 activation status in hT organoids. VINCULIN, loading control. p, phospho.

(B) [35 S]-Met incorporation into protein from KP and KPn organoids treated with DMSO or 1 μ M MK2206 (MK) for 48 hr. Data are means \pm SEM (n = 3, Student's t test).

(C) Lysates from KP and KPn organoids treated with DMSO or 1 μ M MK2206 were subjected to 7-methyl-GTP pull-downs and analyzed for indicated proteins. WCL, whole-cell lysates.

(D) [³⁵S]-Met incorporation into protein from KP organoids treated with 1 μ M MK2206 (MK), 100 μ M BSO, or both for 48 hr. Data are means ± SEM (n = 3, Student's t test). NS, not significant.

(E) Immunoblot analysis of AKT and 4EBP1 activation status in murine (left) and human hT1 (right) T organoids treated with 1 μ M MK2206 (MK), 100 μ M BSO, or both for 48 hr. p, phospho.

(F) Adaptive response in KP organoids (top) and hT organoids (bottom) upon treatment with vehicle only, with 1 μ M MK2206, 100 μ M BSO, or in combination for 48 hr. p = phospho.

(G) Cell viability of N, K, and KP organoids and the corresponding Nrf2-deficient organoids over increasing concentrations of MK2206 for 72 hr. Dotted lines indicate 95% confidence intervals (n = 5).

(H) EC_{50} (half maximal effective concentration) values of MK2206 in murine organoids.

cascades, BSO suppressed the reactivation of EGFR (Figure S6C) and MAPK (Figure 6F) upon treatment with MK2206. Combined treatment of MK2206 with BSO led to a higher level of ROS compared to single agents alone (Figure S6D), further supporting the premise that EGFR autocrine activation in *Kras* mutant cells is redox dependent.

In congruence with our biochemical observations, Kn and KPn organoids were substantially more sensitive to MK2206 (Figures 6G, 6H, and S6E) and the multi-targeted PI3K inhibitor PI-103 (Figure S6F) than K and KP counterparts. Consistently, BSO exhibited a synergistic effect with MK2206 in K and KP organoids (Figures 6I, 6J, S6G, and S6H), as well as in human PDA cells (Figures 6I, 6J, S6I, and S6J). Of note, the sensitivity of N organoids toward MK2206 was not heightened by either BSO treatment (Figures 6I and 6J) or Nrf2 deficiency (Figures 6G and 6H), reflecting a potential therapeutic index.

Contrary to our observations with AKT inhibition, KPn organoids were not more sensitive to mTOR (mammalian target of rapamycin) inhibitors such as rapamycin and Torin1 (Figures S6K and S6L). We posit this to be due to mTOR-mediated growth suppression in cells that rely on extracellular proteins as an amino acid source (Palm et al., 2015), as in the case of Kras mutant cells (Bar-Sagi and Feramisco, 1986). Consistent with the notion that Nrf2 modulates Akt/mTOR activity downstream of mitogenic signaling, elevated levels of lysosomal hydrolysis were observed in KPn organoids (Figure S6M), and this process was redox dependent (Figures S6N and S6O). We posit that the proliferative advantage obtained in mTOR-inhibited Kras mutant cells may outweigh the suppressive effects from AKT and GSH inhibition. Thus, this renders direct antagonism of AKT to be more growth suppressive than that of mTOR in this context. Sensitivity of Nrf2-deficient cells was selective toward inhibition of PI3K/ AKT, as similar vulnerability was absent toward the MEK (MAPK/ERK kinase) inhibitor AZD6244 (Figures S6P and S6Q) (Davies et al., 2007) or toward a panel of commonly used chemotherapeutics (Figure S6R).

Encouraged by our in vitro observations on MK2206 and BSO, we tested this strategy in the KPC mouse model (Hingorani et al., 2005). Mice were randomly assigned to treatments with vehicle, BSO, MK2206, or the combination of MK2206 and BSO. MK2206 and BSO effectively suppressed levels of pAkt (Figure S7A) and GSH (Figure S7B), respectively. While monotherapy did not markedly impact tumor growth, combination treatment was significantly growth suppressive (Figures 7A and 7B). Long-term treatment of KPC mice with this combination diminished neoplastic cell proliferation (Figure S7C) and modestly increased median survival when compared to treatment with MK2206 alone (Figure S7D). The synergistic effect of MK2206 and BSO was also observed in Suit2 xenograft models in terms of tumor kinetics (Figure 7C) and neoplastic cell proliferation (Figure 7D). Our results suggest that pro-oxidants may further augment the effectiveness of AKT inhibition in suppressing PDA growth through combined inhibition of mRNA translation and EGFR-dependent mechanisms of resistance (Figure S7E).

DISCUSSION

The concept that elevated levels of free radicals and oxidative stress contributes to DNA damage and predisposition to cancer has led to the recommendation of antioxidant use as prophylaxis against neoplasia (Khansari et al., 2009). However, Nrf2 activators (Talalay et al., 2007) and various antioxidants have either failed to reduce cancer incidence or have, instead, promoted cancer in clinical and preclinical testing (Sayin et al., 2014). We present the alternative hypothesis that Nrf2's antioxidant function stimulates pancreatic cancer, in part, by promoting mRNA translation and mitogenic signaling. Indeed, our findings may reflect cellular responses to a number of redox perturbants demonstrated previously to exhibit efficacy in *Ras* mutant cells. This includes erastin (Yang and Stockwell, 2008), dehydroascorbic acid (oxidized vitamin C) (Yun et al., 2015), and platinumbased cytotoxics (Socinski, 2004).

The synthetic lethal interaction we observed between Nrf2 loss and oncogenic Kras in PDA may also reflect the proto-oncogenic mRNAs that are exquisitely translationally upregulated in *Kras* mutant cells. For example, Hif1 α , an important transcription factor that mediates adaptive responses to intratumoral hypoxia and malignant progression in PDA (Zhao et al., 2014), was markedly decreased in *Nrf2*-deficient *Kras* mutant cells. Hif1 α likely contributes to the glycolytic phenotype of PDA (Ying et al., 2012), working in parallel with NRF2 transcriptional target genes that are metabolic enzymes governing the pentose phosphate pathway (Mitsuishi et al., 2012) to promote metabolic rewiring in cancer cells.

Regarding the potential clinical implications of this work, AKT inhibitors have already shown some preliminary activity in clinical trials (Molife et al., 2014; Yap et al., 2011), and MK2206 is currently being investigated in patients with pancreatic cancer (https://ClinicalTrials.gov IDs NCT01783171 and NCT01658943). Our present study demonstrates that the combination of AKT inhibitors with oxidizing agents is active in PDA, and ongoing work will determine whether the investigational agent BSO (https://ClinicalTrials.gov IDs NCT00002730, NCT00005835, and NCT00661336) or alternative agents that target different aspects of redox regulation will be most attractive for rapid clinical translation.

EXPERIMENTAL PROCEDURES

Human Specimens

All human experiments were approved by the Institutional Review Boards of Memorial Sloan Kettering Cancer Centre, MD Anderson Cancer Centre, Weill Cornell Medical College, Stony Brook University, and Cold Spring Harbor laboratory. Written informed consent from the donors for research use of tissue in this study was obtained prior to acquisition of the specimen. Samples were confirmed to be tumor or normal based on pathological assessment.

(J) EC_{50} values of MK2206 on pancreatic organoids and cell lines in the presence or absence of BSO. See also Figure S6.

⁽I) Cell viability of N, K, and KP organoids and Suit2 cells over increasing concentrations of MK2206 in the presence or absence of BSO for 72 hr. Dotted lines indicate 95% confidence intervals (n = 5).



Figure 7. Combined Inhibition of AKT and GSH Synthesis Suppresses Human and Mouse Pancreatic Tumor Growth In Vivo (A) Tumor volumes of KPC mice treated daily with vehicle (methylcellulose), BSO, MK2206, or the combination for 7 days. Tumor volumes were determined by ultrasound imaging on the indicated days.

(B) Relative tumor volume of KPC mice treated with MK2206 or in combination with BSO on day 7. Student's t test (n = 11). Data are means ± SEM, Student's t test.

(C) Relative growth of subcutaneously xenografted Suit2 tumors in mice treated with vehicle, MK2206, or MK2206 + BSO for 7 days (left) or 14 days (right). Data are means ± SEM, Student's t test.

(D) Phospho-histone H3 IHC of representative Suit2 tumors from treated mice (left). Quantification of pH 3 positivity (right). Data are means \pm SEM (n \geq 5 fields of view), Student's t test.

See also Figure S7.

Analysis of Global Protein Synthesis

Organoids or Suit2 cells were incubated for 30 min in media containing 10 μ Ci of [³⁵S]-Met (NEG709A005MC, PerkinElmer). Cell lysates were prepared using standard procedures, and equal amounts of total protein were separated on a 4%–12% Bis-Tris polyacrylamide gel and transferred to PVDF (polyvinylidene fluoride) membrane. Membranes were exposed to autoradiography film for 12–48 hr and then developed. For liquid scintillation, equal amounts of radio-labeled total protein were TCA (trichloroacetic acid) precipitated, washed two times in acetone, and air dried at room temperature. The amount of [³⁵S]-Met incorporated into protein was measured using a Beckman LS6500 Scintillation assay (Bio-Rad).

Polysome Fractionation

Organoids were treated with 300 μ g/ml cyclohexamide (Sigma) in media for 10 min at 37°C and then harvested on ice in PBS containing 300 μ g/ml cyclohexamide. Cells were pelleted and lysed in 10 mM Tris-HCl (pH 8), 140 mM NaCl, 1.5 mM MgCl₂, 0.25% NP-40, 0.1% Triton X-100, 50 mM DTT, 150 μ g/ml cyclohexamide, and 640 U/ml RNasin for 30 min. Lysates were cleared, separated on a 10%–50% sucrose gradient by ultracentrifugation, and fractionated using a Teledyne Isco gradient fractionation system.

Therapeutic Intervention Studies in Mice

Upon detection of a mass during weekly palpation, KPC mice were subjected to high-contrast ultrasound imaging using the Vevo 2100 System with an MS250 13- to 24-MHz scanhead (Visual Sonics). Mice with tumor diameters of 7-9 mm were randomized and enrolled 1 day after scanning. MK2206 (Merck) was formulated in 0.5% methylcellulose. BSO (Sigma) was formulated in saline. Mice were administered methylcellulose vehicle or 100 mg/kg MK2206 every day via oral gavage and saline or 10 mmol/kg BSO via intraperitoneal injection. Tumor volume was monitored on days 4 and 7 after initial scan. The same dosing regimen was applied to athymic nude mice bearing Suit2 tumor cells. Drug administration was initiated 3 weeks post-transplantation of 10^5 cells subcutaneously.

ACCESSION NUMBERS

The accession number for the cysteine proteomic dataset reported in this paper is MassIVE: MSV000079394.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, seven figures, and five tables and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2016.06.056.

AUTHOR CONTRIBUTIONS

I.I.C.C. and D.A.T. initiated the project and designed the research plan. S.M.J. helped with translation experiments. M.P.-S. and D.Ö. helped with doseresponse experiments. K.R. performed the mass spectrometry (MS) experiment. J.W., V.S., Y.H., and M.H. performed statistical analysis of MS data. K.W., D.F., Y.P., B.D., and C.S. helped with the in vivo animal study. J.E.W. performed pathological analysis. W.P., C.B.T., and I.I.C.C. designed and performed lysosomal hydrolysis experiments. E.J.L. and Y.P. designed and cloned cysteine mutants. H.T. and J.M.B. established human organoid lines from primary patient samples. G.M.D. provided inducible NRF2 hairpins. H.C.C. assisted in Adam10-related experiments. I.I.C.C., E.E.S., D.J.P., N.S., and D.A.T. designed the study and wrote the manuscript. S.M.J., M.P.-S., and Y.P. contributed equally.

ACKNOWLEDGMENTS

We thank J.R. Prigge, Montana State University, for developing the anti-Nrf2 antibody and Dr. L. Baker for critical review of the manuscript. This work was performed with the CSHL Mass Spectrometry, Animal and Tissue Imaging, and Bioinformatics Shared Resources, which are supported by Cancer Center Support grant 5P30CA045508. D.A.T. is a distinguished scholar of the Lustgarten Foundation (LF) and director of the LF-designated Laboratory of Pancreatic Cancer Research. D.A.T. is supported by the CSHL Association; the NIH (5P30CA45508-26, 5P50CA101955-07, 1U10CA180944-01, 5U01CA168409-3, and 1R01CA190092-01); the Carcinoid Foundation; PCUK; the David Rubinstein Center for Pancreatic Cancer Research at MSKCC; Stand Up to Cancer/KWF; the STARR Foundation (I7-A718), the DOD (W81XWH-13-PRCRP-IA); and the Precision Medicine Research Associates. We are also grateful for support from the following: the Damon Runyon Cancer Research Foundation (Shirley Stein fellow, DRG-2165-13, to I.I.C.C.); the Human Frontier Science Program (LT000190/2013 to I.I.C.C.); the Cancer Research Society and CCSRI (702317, N.S.); the Canadian Institute of Health Research (to S.M.J.); NIH (grants AG040020 and CA152559 to E.E.S.; grant R01 CA159222 to H.C.C.); the Swedish Research Council (537-2013-7277 to D.Ö.), the Sociedad Española de Oncología Médica (SEOM; to M.P.-S.); and the Hope Funds for Cancer Research Fellowship (to W.P). This work was performed with the MSKCC Molecular Cytology Core, which is supported by Cancer Center Support grant P30CA008748. C.B.T. is a founder of Agios Pharmaceuticals and a member of its scientific advisory board. C.B.T. also serves on the board of directors of Merck.

Received: November 29, 2015 Revised: May 5, 2016 Accepted: June 29, 2016 Published: July 28, 2016

REFERENCES

Anastasiou, D., Poulogiannis, G., Asara, J.M., Boxer, M.B., Jiang, J.K., Shen, M., Bellinger, G., Sasaki, A.T., Locasale, J.W., Auld, D.S., et al. (2011). Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science *334*, 1278–1283.

Ardito, C.M., Grüner, B.M., Takeuchi, K.K., Lubeseder-Martellato, C., Teichmann, N., Mazur, P.K., Delgiorno, K.E., Carpenter, E.S., Halbrook, C.J., Hall, J.C., et al. (2012). EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell *22*, 304–317.

Bar-Sagi, D., and Feramisco, J.R. (1986). Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. Science 233, 1061–1068.

Barford, D. (2004). The role of cysteine residues as redox-sensitive regulatory switches. Curr. Opin. Struct. Biol. *14*, 679–686.

Belalcázar, A.D., Ball, J.G., Frost, L.M., Valentovic, M.A., and Wilkinson, J., 4th. (2014). Transsulfuration is a significant source of sulfur for glutathione production in human mammary epithelial cells. ISRN Biochem. *2013*, 637897.

Cell

Bilanges, B., and Stokoe, D. (2007). Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies. Oncogene *26*, 5973–5990.

Boj, S.F., Hwang, C.I., Baker, L.A., Chio, I.I., Engle, D.D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M.S., et al. (2015). Organoid models of human and mouse ductal pancreatic cancer. Cell *160*, 324–338.

Brandes, N., Reichmann, D., Tienson, H., Leichert, L.I., and Jakob, U. (2011). Using quantitative redox proteomics to dissect the yeast redoxome. J. Biol. Chem. *286*, 41893–41903.

Choo, A.Y., and Blenis, J. (2009). Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle *8*, 567–572.

Davies, B.R., Logie, A., McKay, J.S., Martin, P., Steele, S., Jenkins, R., Cockerill, M., Cartlidge, S., and Smith, P.D. (2007). AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/ pharmacodynamic relationship, and potential for combination in preclinical models. Mol. Cancer Ther. 6, 2209–2219.

DeNicola, G.M., Karreth, F.A., Humpton, T.J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K.H., Yeo, C.J., Calhoun, E.S., et al. (2011). Oncogeneinduced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106–109.

Fan, X., Chen, P., Tan, H., Zeng, H., Jiang, Y., Wang, Y., Wang, Y., Hou, X., Bi, H., and Huang, M. (2014). Dynamic and coordinated regulation of KEAP1-NRF2-ARE and p53/p21 signaling pathways is associated with acetaminophen injury responsive liver regeneration. Drug Metab. Dispos. *42*, 1532–1539. Gingras, A.C., Gygi, S.P., Raught, B., Polakiewicz, R.D., Abraham, R.T., Hoek-

stra, M.F., Aebersold, R., and Sonenberg, N. (1999). Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. *13*, 1422–1437.

Hayes, J.D., and Dinkova-Kostova, A.T. (2014). The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci. *39*, 199–218.

Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B., Hruban, R.H., Rustgi, A.K., Chang, S., and Tuveson, D.A. (2005). Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469–483.

Huang, W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. *4*, 44–57.

Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., and Thun, M.J. (2009). Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249.

Johnson, L.F., Williams, J.G., Abelson, H.T., Green, H., and Penman, S. (1975). Changes in RNA in relation to growth of the fibroblast. III. Posttranscriptional regulation of mRNA formation in resting and growing cells. Cell *4*, 69–75.

Jones, S., Zhang, X., Parsons, D.W., Lin, J.C., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science *321*, 1801–1806.

Ke, B., Shen, X.D., Zhang, Y., Ji, H., Gao, F., Yue, S., Kamo, N., Zhai, Y., Yamamoto, M., Busuttil, R.W., and Kupiec-Weglinski, J.W. (2013). KEAP1-NRF2 complex in ischemia-induced hepatocellular damage of mouse liver transplants. J. Hepatol. *59*, 1200–1207.

Khansari, N., Shakiba, Y., and Mahmoudi, M. (2009). Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat. Inflamm. Allergy Drug Discov. *3*, 73–80.

Ling, J., and Söll, D. (2010). Severe oxidative stress induces protein mistranslation through impairment of an aminoacyl-tRNA synthetase editing site. Proc. Natl. Acad. Sci. USA *107*, 4028–4033.

Maehama, T., and Dixon, J.E. (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-tri-sphosphate. J. Biol. Chem. *273*, 13375–13378.

Malec, V., Gottschald, O.R., Li, S., Rose, F., Seeger, W., and Hänze, J. (2010). HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. Free Radic. Biol. Med. 48, 1626–1635.

Mavrakis, K.J., and Wendel, H.G. (2008). Translational control and cancer therapy. Cell Cycle 7, 2791–2794.

Mendoza, M.C., Er, E.E., and Blenis, J. (2011). The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 36, 320–328.

Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., and Motohashi, H. (2012). Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell *22*, 66–79.

Molife, L.R., Yan, L., Vitfell-Rasmussen, J., Zernhelt, A.M., Sullivan, D.M., Cassier, P.A., Chen, E., Biondo, A., Tetteh, E., Siu, L.L., et al. (2014). Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J. Hematol. Oncol. 7, 1.

Molina-Arcas, M., Hancock, D.C., Sheridan, C., Kumar, M.S., and Downward, J. (2013). Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov. *3*, 548–563.

Moore, P.S., Sipos, B., Orlandini, S., Sorio, C., Real, F.X., Lemoine, N.R., Gress, T., Bassi, C., Kloppel, G., Kalthoff, H., et al. (2001). Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/ Smad4. Virchows Arch. *439*, 798–802.

Niture, S.K., and Jaiswal, A.K. (2012). Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J. Biol. Chem. 287, 9873–9886.

Otto, G.A., and Puglisi, J.D. (2004). The pathway of HCV IRES-mediated translation initiation. Cell *119*, 369–380.

Palm, W., Park, Y., Wright, K., Pavlova, N.N., Tuveson, D.A., and Thompson, C.B. (2015). The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1. Cell *162*, 259–270.

Patel, M.R., Jay-Dixon, J., Sadiq, A.A., Jacobson, B.A., and Kratzke, R.A. (2013). Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC. J. Thorac. Oncol. 8, 1142–1147.

Paulsen, C.E., and Carroll, K.S. (2010). Orchestrating redox signaling networks through regulatory cysteine switches. ACS Chem. Biol. 5, 47–62.

Pelletier, J., Graff, J., Ruggero, D., and Sonenberg, N. (2015). Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res. 75, 250–263.

Permyakov, S.E., Zernii, E.Y., Knyazeva, E.L., Denesyuk, A.I., Nazipova, A.A., Kolpakova, T.V., Zinchenko, D.V., Philippov, P.P., Permyakov, E.A., and Senin, I.I. (2012). Oxidation mimicking substitution of conservative cysteine in recoverin suppresses its membrane association. Amino Acids *42*, 1435–1442.

Raught, B., Gingras, A.C., Gygi, S.P., Imataka, H., Morino, S., Gradi, A., Aebersold, R., and Sonenberg, N. (2000). Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J. *19*, 434–444.

Ross, P.L., Huang, Y.N., Marchese, J.N., Williamson, B., Parker, K., Hattan, S., Khainovski, N., Pillai, S., Dey, S., Daniels, S., et al. (2004). Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 3, 1154–1169.

Ruggero, D., and Sonenberg, N. (2005). The Akt of translational control. Oncogene 24, 7426–7434.

Sahin, U., Weskamp, G., Kelly, K., Zhou, H.M., Higashiyama, S., Peschon, J., Hartmann, D., Saftig, P., and Blobel, C.P. (2004). Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J. Cell Biol. *164*, 769–779. Sayin, V.I., Ibrahim, M.X., Larsson, E., Nilsson, J.A., Lindahl, P., and Bergo, M.O. (2014). Antioxidants accelerate lung cancer progression in mice. Sci. Transl. Med. 6, 221ra15.

Semenza, G.L. (2013). HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest. *123*, 3664–3671.

Sethuraman, M., McComb, M.E., Huang, H., Huang, S., Heibeck, T., Costello, C.E., and Cohen, R.A. (2004). Isotope-coded affinity tag (ICAT) approach to redox proteomics: identification and quantitation of oxidant-sensitive cysteine thiols in complex protein mixtures. J. Proteome Res. 3, 1228–1233.

Siegel, R.L., Miller, K.D., and Jemal, A. (2015). Cancer statistics, 2015. CA Cancer J. Clin. 65, 5–29.

Socinski, M.A. (2004). Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms. Clin. Cancer Res. *10*, 4210s–4214s.

Sonenberg, N., and Hinnebusch, A.G. (2009). Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell *136*, 731–745.

Talalay, P., Fahey, J.W., Healy, Z.R., Wehage, S.L., Benedict, A.L., Min, C., and Dinkova-Kostova, A.T. (2007). Sulforaphane mobilizes cellular defenses that protect skin against damage by UV radiation. Proc. Natl. Acad. Sci. USA *104*, 17500–17505.

Trachootham, D., Lu, W., Ogasawara, M.A., Nilsa, R.D., and Huang, P. (2008). Redox regulation of cell survival. Antioxid. Redox Signal. *10*, 1343–1374.

Ueda, T., Watanabe-Fukunaga, R., Fukuyama, H., Nagata, S., and Fukunaga, R. (2004). Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol. Cell. Biol. *24*, 6539–6549.

Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al. (2016). NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Sci. Transl. Med. *8*, 334ra51.

Wendel, H.G., De Stanchina, E., Fridman, J.S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., and Lowe, S.W. (2004). Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature *428*, 332–337.

Wilson, J.E., Powell, M.J., Hoover, S.E., and Sarnow, P. (2000). Naturally occurring dicistronic cricket paralysis virus RNA is regulated by two internal ribosome entry sites. Mol. Cell. Biol. 20, 4990–4999.

Yang, W.S., and Stockwell, B.R. (2008). Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in onco-genic-RAS-harboring cancer cells. Chem. Biol. *15*, 234–245.

Yap, T.A., Yan, L., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K., Baird, R.D., Delgado, L., Taylor, A., Lupinacci, L., et al. (2011). First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J. Clin. Oncol. *29*, 4688–4695.

Ying, H., Kimmelman, A.C., Lyssiotis, C.A., Hua, S., Chu, G.C., Fletcher-Sananikone, E., Locasale, J.W., Son, J., Zhang, H., Coloff, J.L., et al. (2012). Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell *149*, 656–670.

Yun, J., Mullarky, E., Lu, C., Bosch, K.N., Kavalier, A., Rivera, K., Roper, J., Chio, I.I., Giannopoulou, E.G., Rago, C., et al. (2015). Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science *350*, 1391–1396.

Zetterberg, A., Larsson, O., and Wiman, K.G. (1995). What is the restriction point? Curr. Opin. Cell Biol. 7, 835–842.

Zhao, X., Gao, S., Ren, H., Sun, W., Zhang, H., Sun, J., Yang, S., and Hao, J. (2014). Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin. Cancer Res. *74*, 2455–2464.